TORL-2-307-MAB
/ TORL Biotherap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 09, 2024
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
(clinicaltrials.gov)
- P1 | N=70 | Active, not recruiting | Sponsor: TORL Biotherapeutics, LLC | Recruiting ➔ Active, not recruiting
Enrollment closed • Metastases • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
February 08, 2022
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
(clinicaltrials.gov)
- P1 | N=70 | Recruiting | Sponsor: TORL Biotherapeutics, LLC | Not yet recruiting ➔ Recruiting
Enrollment open • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
1 to 2
Of
2
Go to page
1